Elaris FlexCo

Elaris is an emerging biotechnology company based in Austria that specializes in the development of next-generation targeted protein degradation (TPD) therapies. The company utilizes a proprietary platform to design small molecules capable of eliminating disease-causing proteins that were previously considered undruggable. Currently in the pre-clinical stage, Elaris focuses on high-impact therapeutic areas including oncology and inflammatory diseases. By leveraging advanced medicinal chemistry and degradation biology, the company aims to provide more effective and precise treatment options for patients with limited therapeutic alternatives.